<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumour</z:e> budding in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is established as a poor prognostic factor </plain></SENT>
<SENT sid="1" pm="."><plain>The inverse correlation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> buds with peritumoural lymphocytic <z:mp ids='MP_0001845'>inflammation</z:mp> suggests an interaction with specific immune responses </plain></SENT>
<SENT sid="2" pm="."><plain>The aims of this study were to characterize the immunological microenvironment of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> buds and its impact on prognosis in mismatch repair (MMR)-proficient and -deficient <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: A total of 297 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> were double-immunostained for CK22 plus one of the following: CD138, CD16, CD20, CD21, CD56, CD68, CD8, forkhead box P2 (FoxP3), granzyme B, mast cell tryptase, CD3 or T cell intracellular antigen-1 (<z:hpo ids='HP_0002326'>TIA</z:hpo>)-1 </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumour</z:e> buds and immune cells within the region of densest budding were evaluated [Ã—40 high-power field (HPF)] simultaneously </plain></SENT>
<SENT sid="5" pm="."><plain>In both MMR-proficient and -deficient <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, CD8(+), FoxP3(+) and CD68(+) cells were observed most frequently (&gt;40 cells/HPF) and were independent prognostic factors </plain></SENT>
<SENT sid="6" pm="."><plain>A combined prognostic score of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> budding and CD8(+), FoxP3(+) and CD68(+) distinctly identified patients with low-, moderate- or high-risk <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> with 5-year survival rates of 75.2% [confidence interval 95% (CI): 66-83], 56.3% (95% CI: 43-68) and 25.2% (95% CI: 14-38), respectively, in MMR-proficient and -deficient <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: The combined assessment of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> budding with CD8, FoxP3 and CD68 lymphocytes could represent a basis for a prognostic score similar to the Bloom Richardson grade (BRE) and Gleason scores for breast and <z:hpo ids='HP_0012125'>prostatic cancers</z:hpo> </plain></SENT>
</text></document>